NEUWAY Pharma
NEUWAY Pharma is developing an entirely novel class of biotherapeutics built around its proprietary Engineered Protein Capsules (EnPC®), which can cross the blood-brain barrier and deliver transformative neuropharmaceuticals for the treatment of disorders of the central nervous system (CNS).
The company aims to be the partner of choice for developers of mRNA drug candidates and other drug modalities who need to overcome the current hurdles of delivering these into the brain and CNS tissue.
Operating as a drug developer and a delivery expert, NEUWAY will demonstrate and exploit the value of its technology through its internal rare disease pipeline for indications with a high unmet medical need as well as partnered programs.
Meet us
March 13-14, 2024
OPT Congress Oligonucleotides & mRNA Therapeutics, Boston, USA
Ekkehard Leberer, PhD, Professor of Biochemistry, Advisor at NEUWAY Pharma GmbH
April 10-12, 2024
EUROPEAN SYMPOSIUM ON CONTROLLED DRUG DELIVERY,EGMOND AAN ZEE, NETHERLANDS.
Heiko Manninga, PhD, Managing Director, NEUWAY Pharma GmbH